During BIC22, Roche confirmed the solid (recovery) momentum in Core Pharmas, along with ample support from less severe biosimilar headwinds and COVID-19 business’s moderation, confidence with respect to Alzheimer’s drug and promising dynamics in Diagnostics. Although, near-term margins are likely to be restrained by R&D ambitions. Also, an inclination towards smaller acquisitions was reiterated. Overall, the Swiss giant remains on the right track to make-up for the (R&D and/or operational) disap ....

20 Sep 2022
BIC22 takeaways

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BIC22 takeaways
- Published:
20 Sep 2022 -
Author:
Amandeep Goyal -
Pages:
3 -
During BIC22, Roche confirmed the solid (recovery) momentum in Core Pharmas, along with ample support from less severe biosimilar headwinds and COVID-19 business’s moderation, confidence with respect to Alzheimer’s drug and promising dynamics in Diagnostics. Although, near-term margins are likely to be restrained by R&D ambitions. Also, an inclination towards smaller acquisitions was reiterated. Overall, the Swiss giant remains on the right track to make-up for the (R&D and/or operational) disap ....